# VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

> **NCT05364242** · PHASE2,PHASE3 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 178 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** VLA2001

## Key facts

- **NCT ID:** NCT05364242
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2022-09-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364242, "VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05364242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*